08-09-2022 дата публикации
Номер: US20220281872A1
The present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof; and a use thereof in preparing drugs used to treat EZH2-mediated disease. 3. The compound according to claim 1 , wherein{'sub': 1', '1', '6, 'Ris selected from halogen or C-Calkyl;'}{'sub': 2', '4', '5', '4', '5', '6', '6', '1', '6, 'Ris selected from —CRR, —NRRor 5-6-membered heteroaryl, wherein the heteroaryl is optionally substituted by one or more R, and Ris C-Calkyl optionally substituted by hydroxyl or cyano;'}{'sub': '3', 'Ris selected from hydrogen or halogen;'}{'sub': 4', '5', '1', '6', '1', '6, 'Rand Rare each independently selected from C-Calkyl, C-Calkoxy or 4-6-membered heterocycly;'}U, V, and L are each independently selected from C or N, and at least one of U, V or L is N;{'sub': 7', '1', '6, 'Ris selected from hydrogen or C-Calkyl;'}n=0 or 1; and{'img': {'@id': 'CUSTOM-CHARACTER-00007', '@he': '3.22mm', '@wi': '12.36mm', '@file': 'US20220281872A1-20220908-P00001.TIF', '@alt': 'custom-character', '@img-content': 'character', '@img-format': 'tif'}, 'represents a single bond or a double bond.'}7. A pharmaceutical composition claim 1 , comprising a therapeutically effective amount of the compound according to or a pharmaceutically acceptable salt claim 1 , ester claim 1 , prodrug claim 1 , complex claim 1 , solvate claim 1 , hydrate or isomer thereof claim 1 , and a pharmaceutically acceptable carrier or excipient.8. A method for treating an EZH2-mediated disease claim 1 , comprising: administering to a patient in need thereof an effective amount of the compound according to or a pharmaceutically acceptable salt claim 1 , ester claim 1 , prodrug claim 1 , complex claim 1 , solvate claim 1 , hydrate or isomer thereof.9. The method according to claim 8 , wherein the disease is cancer.10. The method according to claim 9 , wherein the cancer is lung cancer claim 9 , gastric cancer claim 9 ...
Подробнее